Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Conference News EuroPCR 2023

For Bifurcation Lesions, It’s OK to Start With Just One Stent: EBC Trials

Caitlin E. Cox

May 17, 2023

News Daily News

Big Tobacco Bets on Menthol to Hook Youth, Women, and Blacks

Michael O'Riordan

October 07, 2022

News Daily News

New Tool Helps Balance Bleeding and Thrombotic Risks After PCI

Yael L. Maxwell

January 13, 2021

Presentation TCT 2019

BIOFREEDOM: The LEADERS FREE Program and Beyond

Presenter: Philip Urban

September 28, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

News Conference News EuroPCR 2018

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

Caitlin E. Cox

May 22, 2018

Presentation TCT 2017

BioFreedom: LEADERS FREE Long-term Results and LEADERS FREE II Design

Presenter: Mitchell W. Krucoff, Chaim S. Lotan, Philip M. Urban

November 01, 2017

Presentation TCT 2017

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Presenter: Giulio G. Stefanini, Stephan Windecker, Philip M. Urban

October 30, 2017

Podcast TCTMD Talking Points

Episode 23: LEADERS FREE - Two-Year Clinical and Subgroup Outcomes

June 21, 2017

Advertisement

Use of Secondary CVD Prevention Meds Still Meager Worldwide

For Bifurcation Lesions, It’s OK to Start With Just One Stent: EBC Trials

Big Tobacco Bets on Menthol to Hook Youth, Women, and Blacks

New Tool Helps Balance Bleeding and Thrombotic Risks After PCI

BIOFREEDOM: The LEADERS FREE Program and Beyond

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

New Clarity on Patients at High Risk for Bleeding After PCI

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

FFR in PCI for Stable CAD: Lasting Benefit Shown by FAME 2, SCAAR Data

BioFreedom: LEADERS FREE Long-term Results and LEADERS FREE II Design

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Episode 23: LEADERS FREE - Two-Year Clinical and Subgroup Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content